The Banana is dying out. The race is on to reinvent it before it's too late
The world's most popular fruit is facing extinction, and scientists are racing to use gene-editing…
read moreThe UK Innovation & Science Seed Fund is a £24m, early-stage venture capital fund dedicated to kick-starting promising technology companies developed at some of the UK’s largest publicly-funded research facilities. These companies are linked to the rapidly expanding science and technology campuses and the field of synthetic biology.
Created in 2002, the UK Innovation & Science Seed Fund is backed by ten UK publicly-funded research organisations and the Department of Business, Innovation and Skills (BIS). The Fund holds investments in some of the UK’s most innovative companies in areas as diverse as novel antibiotics, research into Alzheimer’s disease, “green” chemicals and airport security.
We’re prepared to invest early and help build a commercial proposition around a technology to attract additional investment needed to get to market.
1. Projects and companies arising from the world-class research carried out in our Partner laboratories across the UK, including those at Rutherford Appleton Laboratory (STFC), Porton Down (Dstl) and Babraham Institute (BBSRC). View full list of partners.
2. Companies based at our partners’ national science and innovation campuses in Oxford, Cambridge, Warrington and Norwich. Read more about partner campuses.
3. Companies working in the field of synthetic biology: Synthetic biology is an exciting new discipline based on the design and engineering of biologically-based parts, novel devices and systems and the redesign of existing, natural biological systems.
Over the past decade, the UK Innovation & Science Seed Fund has:
The UK Innovation & Science Seed Fund is independently managed by Dr. Andrew Muir and Mark White at Midven.
The world's most popular fruit is facing extinction, and scientists are racing to use gene-editing…
read morePhoto Glialign CEO John Sinden London, 2nd May 2018 The UCL Technology Fund (UCLTF), UK Innovation…
read moreSoftware leader in the field of genomic data and bioinformatics analysis poised for growth 30…
read moreProduction of CCS1477 in capsule form is now complete, ahead of forthcoming first-in-human clinical trials…
read moreThe UK Innovation & Science Seed Fund (UKI2S) - formerly known as Rainbow Seed Fund…
read moreA Smart Textiles Technology Developed at the National Physical Laboratory UK Innovation & Science Seed…
read moreSpinout developing novel hand-held reader to help in the fight against antibiotic resistance UK Innovation…
read moreNemesis Bioscience today announced the successful completion of its latest funding round, bringing total seed…
read moreMay 03, 2017 Justin Petrone www.genomeweb.com British molecular diagnostics company Cytox plans to make…
read moreCollaboration to generate tumor targeting drug conjugates and immuno-oncology therapeutics Crescendo Biologics Limited (Crescendo), the…
read moreSpin out from UK publicly-funded research develops novel laser spectroscopy for environmental, medical diagnosis and…
read moreSynthace Ltd., a London based technology company developing Antha, a high level language and operating…
read moreQuethera Ltd, a privately funded gene therapy company based at the Babraham Research Campus in…
read moreCambridge, UK: 2 February 2016 – Crescendo Biologics Limited (Crescendo), the drug discovery and developer…
read moreJanuary 7th, 2016 -- Contego announces today that it is part of the Accenture FinTech…
read moreAntibody veteran joins new CEO as Crescendo redirects strategy to Oncology focus Cambridge, UK: 17…
read moreCrescendo Biologics Limited, the drug discovery and developer of Humabody™ VH therapeutics, has announced the…
read moreRead the thoughts of Chris Martin Non Executive Directors on the UKI2S Seed Advisory board…
read moreSynthace and Dow AgroSciences LLC, a wholly owned subsidiary of The Dow Chemical Company (NYSE:DOW), today…
read moreDesktop Genetics Ltd (“DTG” or “the Com pany”), a UK bioinformatics company aiming to…
read moreQuethera, a gene therapy company developing a treatment for glaucoma that could prevent blindness, has…
read moreOxford Space Systems (OSS) has successfully secured £1.2m in its second round fund raise from…
read moreWorld Economic Forum today announced its selection of the world’s 49 most promising Technology Pioneers…
read more20 July 2015: Oxford, UK. Cytox Ltd, an innovative developer of assays for risk assessment…
read moreITER, the international fusion reactor being built in France, will stand 10 stories tall, weigh…
read moreCombining excellence in industrial biotechnology May 18th, 2015 – Welwyn Garden City, UK and Baltimore,…
read moreFund Adds Life Science Commercialisation Expert Oliver Sexton to Investment Team and Renewables Entrepreneur Sean…
read more18 July 2014 - Spectral Edge announces today the completion of a £300K financing round…
read moreParts of our planet are so hostile they are unreachable. But if we are to…
read moreVH domains are the smallest, most robust antibody fragments and as such have advantages for…
read moreNew investment coupled with a major award from the UK’s innovation agency, the Technology Strategy…
read moreKEIT Ltd is a brand new, forward thinking spin out company from the Science and…
read moreA Company which offers bespoke microbiological testing has secured £100,000 investment. Perfectus Biomed, based at…
read moreSuitable for low temperatures and high vibrations, immune to EMI Reduces system weight and complexity…
read moreNicOx enters into option agreement to acquire Altacor as a first step towards building an…
read moreTue, 17/01/2012 - 12:26 Cobalt Light Systems has received European approval for its revolutionary INSIGHT100…
read moreNovacta Biosystems has commenced dosing of the first healthy volunteers in a phase 1 clinical…
read moreJust one drop of liquid can destroy your phone or tablet! Acting like a barrier,…
read moreCambridge, UK. 22 June 2011 – Crescendo Biologics Limited (Crescendo) today announces the appointment of…
read moreUK. 12 October 2009 - Mike Romanos has been appointed Chief Scientific Officer of Crescendo…
read moreSummary: ZuvaSyntha is developing proprietary renewable manufacturing routes to industrial chemicals from low cost…
read more